# Wilm's Tumor 1 Protein Vaccine to Treat Cancers of the Blood

> **NCT00923910** · PHASE1,PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 10 (actual)

## Conditions studied

- Leukemia, Acute Myelogenous (AML)
- Leukemia, Acute Lymphocytic (ALL)
- Leukemia, Chronic Myelogenous (CML)
- Myelodysplastic Syndrome (MDS)
- Non-Hodgkin's Lymphoma (NHL)

## Interventions

- **DRUG:** WT1 Peptide-Pulsed Dendritic Cells
- **DRUG:** Donor Lymphocytes
- **DRUG:** IL-4
- **DRUG:** KLH
- **DRUG:** WT1 Peptides
- **DRUG:** Endotoxin
- **DRUG:** Diphenhydramine
- **DRUG:** Acetaminophen

## Key facts

- **NCT ID:** NCT00923910
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-02-22
- **Primary completion:** 2013-10-18
- **Final completion:** 2016-11-15
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2017-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00923910

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00923910, "Wilm's Tumor 1 Protein Vaccine to Treat Cancers of the Blood". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT00923910. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*